Go Pro
→ Why This Small AI Company Holds 150 Patents (From Brownstone Research) (Ad)tc pixel Free PRAX Stock Alerts

Praxis Precision Medicines (PRAX) Financials

Praxis Precision Medicines logo
$298.95 -11.52 (-3.71%)
Closing price 04:00 PM Eastern
Extended Trading
$297.81 -1.14 (-0.38%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Praxis Precision Medicines

Annual Income Statements for Praxis Precision Medicines

This table shows Praxis Precision Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -41 -70 -167 -214 -123 -183 -303
Consolidated Net Income / (Loss)		 -36 -62 -167 -214 -123 -183 -303
Net Income / (Loss) Continuing Operations		 -36 -62 -167 -214 -123 -183 -303
Total Pre-Tax Income 		-36 -62 -167 -214 -123 -183 -303
Total Operating Income		 -36 -62 -167 -215 -126 -200 -326
Total Gross Profit		 0.00 0.00 0.00 0.00 2.45 8.55 0.00
Total Revenue		 0.00 0.00 0.00 0.00 2.45 8.55 0.00
Operating Revenue		 - - - 0.00 - - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 36 62 167 215 129 209 326
Selling, General & Admin Expense		 6.23 17 47 60 42 56 59
Research & Development Expense		 30 45 120 155 87 152 267
Total Other Income / (Expense), net		 0.19 0.28 0.27 0.96 3.10 17 23
Other Income / (Expense), net		 - 0.14 - 0.96 3.10 17 23
Basic Earnings per Share		 ($26.60) ($7.86) ($3.94) ($69.65) ($18.69) ($10.21) ($13.48)
Weighted Average Basic Shares Outstanding		 1.53M 8.95M 42.45M 3.07M 6.59M 17.91M 22.50M
Diluted Earnings per Share		 ($26.60) ($7.86) ($3.94) ($69.65) ($18.69) ($10.21) ($13.48)
Weighted Average Diluted Shares Outstanding		 1.53M 8.95M 42.45M 3.07M 6.59M 17.91M 22.50M
Weighted Average Basic & Diluted Shares Outstanding		 1.53M 8.95M 45.49M 52.39M 13.24M 20.16M 27.85M

Quarterly Income Statements for Praxis Precision Medicines

This table shows Praxis Precision Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93 -84
Consolidated Net Income / (Loss)		 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93 -84
Net Income / (Loss) Continuing Operations		 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93 -84
Total Pre-Tax Income 		-27 -40 -33 -52 -59 -69 -71 -74 -89 -93 -84
Total Operating Income		 -28 -42 -37 -57 -64 -75 -76 -78 -97 -106 -97
Total Gross Profit		 0.52 0.43 0.36 0.30 7.46 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 0.52 0.43 0.36 0.30 7.46 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 28 42 38 57 71 75 76 78 97 106 97
Selling, General & Admin Expense		 9.93 15 11 15 15 14 13 13 20 28 27
Research & Development Expense		 18 27 27 42 56 61 63 66 78 78 69
Total Other Income / (Expense), net		 0.93 2.33 4.81 4.93 5.28 5.43 4.94 4.43 8.13 13 13
Other Income / (Expense), net		 0.93 2.33 4.81 4.93 5.28 5.43 4.94 4.43 8.13 13 13
Basic Earnings per Share		 ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20) ($2.87)
Weighted Average Basic Shares Outstanding		 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M 29.13M
Diluted Earnings per Share		 ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20) ($2.87)
Weighted Average Diluted Shares Outstanding		 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M 29.13M
Weighted Average Basic & Diluted Shares Outstanding		 13.24M 17.11M 17.76M 18.64M 20.16M 20.37M 21.05M 25.01M 27.85M 27.88M 27.92M

Annual Cash Flow Statements for Praxis Precision Medicines

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 27 252 -157 -78 20 134 142
Net Cash From Operating Activities		 -33 -53 -125 -185 -111 -132 -249
Net Cash From Continuing Operating Activities		 -33 -53 -125 -185 -110 -131 -250
Net Income / (Loss) Continuing Operations		 -36 -62 -167 -214 -123 -183 -303
Consolidated Net Income / (Loss)		 -36 -62 -167 -214 -123 -183 -303
Depreciation Expense		 0.04 0.05 0.18 0.42 0.43 0.36 0.14
Amortization Expense		 - 0.00 2.09 1.00 0.05 -5.01 -3.59
Non-Cash Adjustments To Reconcile Net Income		 1.31 5.91 24 29 26 45 33
Changes in Operating Assets and Liabilities, net		 0.75 3.24 16 -1.78 -13 12 24
Net Cash From Investing Activities		 -0.10 0.00 -141 97 39 -248 -311
Net Cash From Continuing Investing Activities		 -0.10 0.00 -141 97 39 -248 -311
Purchase of Property, Plant & Equipment		 -0.10 0.00 -1.05 -0.44 -0.05 0.00 -0.06
Purchase of Investments		 - 0.00 -164 -83 0.00 -372 -624
Sale and/or Maturity of Investments		 - 0.00 25 180 39 123 313
Net Cash From Financing Activities		 60 304 108 10 92 514 702
Net Cash From Continuing Financing Activities		 60 304 108 10 92 514 702
Issuance of Common Equity		 0.00 201 106 11 92 515 704
Other Financing Activities, net		 0.00 0.09 2.45 -0.26 -0.14 -0.31 -2.09

Quarterly Cash Flow Statements for Praxis Precision Medicines

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -20 71 -6.84 24 47 -50 -8.15 -7.89 208 179 -62
Net Cash From Operating Activities		 -24 -21 -27 -28 -56 -53 -55 -65 -76 -86 -78
Net Cash From Continuing Operating Activities		 -23 -21 -27 -28 -56 -53 -54 -65 -77 -86 -77
Net Income / (Loss) Continuing Operations		 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93 -84
Consolidated Net Income / (Loss)		 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93 -84
Depreciation Expense		 0.11 0.11 0.11 0.09 0.05 0.05 0.05 0.02 0.03 0.04 0.03
Amortization Expense		 - -0.08 -1.53 -2.01 -1.39 -1.23 -0.99 -0.71 -0.67 -0.66 -0.69
Non-Cash Adjustments To Reconcile Net Income		 7.12 17 6.11 13 8.82 9.04 8.58 7.71 7.90 17 12
Changes in Operating Assets and Liabilities, net		 -3.78 1.47 0.72 14 -4.92 8.74 9.06 1.85 4.29 -10 -4.45
Net Cash From Investing Activities		 -0.05 -91 -196 50 -11 -51 18 50 -328 -344 11
Net Cash From Continuing Investing Activities		 - -91 -196 50 -11 -51 18 50 -328 -344 11
Purchase of Property, Plant & Equipment		 - - - - - 0.00 0.01 - - -0.06 -1.02
Purchase of Investments		 - -91 -199 -12 -69 -117 -41 -75 -390 -487 -77
Sale and/or Maturity of Investments		 - 0.00 3.00 62 59 66 59 126 62 143 89
Net Cash From Financing Activities		 4.13 183 216 1.44 114 54 29 6.76 613 609 4.57
Net Cash From Continuing Financing Activities		 4.13 183 216 1.44 114 54 29 6.76 613 609 4.57
Other Financing Activities, net		 -0.01 0.01 -0.01 -0.00 -0.16 -0.64 -0.58 -0.05 -0.82 -12 4.57

Annual Balance Sheets for Praxis Precision Medicines

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 48 303 293 115 88 483 938
Total Current Assets		 45 302 287 111 85 404 611
Cash & Equivalents		 45 297 139 62 81 215 357
Short-Term Investments		 - 0.00 137 39 0.00 177 242
Prepaid Expenses		 0.68 5.72 11 10 3.58 12 12
Plant, Property, & Equipment, net		 0.13 0.08 1.21 0.97 0.59 0.23 0.15
Total Noncurrent Assets		 2.07 0.77 4.13 3.32 2.48 79 327
Long-Term Investments		 - - - - 0.00 77 327
Intangible Assets		 - - - - - - 0.00
Other Noncurrent Operating Assets		 2.07 0.77 4.13 3.32 2.48 1.55 0.09
Total Liabilities & Shareholders' Equity		 48 303 293 115 88 483 938
Total Liabilities		 7.58 16 42 39 18 38 60
Total Current Liabilities		 6.82 16 38 34 16 38 60
Accounts Payable		 2.67 4.09 11 15 5.82 13 25
Accrued Expenses		 3.46 11 27 16 7.42 24 35
Other Current Liabilities		 0.70 0.76 0.81 1.01 1.13 1.26 0.11
Total Noncurrent Liabilities		 0.76 0.00 3.50 4.68 2.53 0.11 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -81 287 251 76 70 445 878
Total Preferred & Common Equity		 -81 287 251 76 70 445 878
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -81 287 251 76 70 445 878
Common Stock		 0.00 437 568 607 724 1,282 2,018
Retained Earnings		 -81 -150 -317 -531 -654 -837 -1,140
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.18 -0.17 0.00 0.65 0.56

Quarterly Balance Sheets for Praxis Precision Medicines

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 98 133 107 250 441 416 479 453 396 1,460 1,390
Total Current Assets		 94 130 103 212 357 360 334 307 274 798 772
Cash & Equivalents		 81 124 101 152 145 169 166 157 150 536 475
Short-Term Investments		 4.98 0.00 0.00 55 207 188 162 144 118 251 284
Prepaid Expenses		 8.58 5.53 2.24 4.39 4.84 3.02 5.58 5.30 6.69 11 13
Plant, Property, & Equipment, net		 0.87 0.76 0.70 0.48 0.37 0.28 0.25 0.26 0.17 0.17 0.49
Total Noncurrent Assets		 3.12 2.91 2.70 38 84 56 145 146 122 662 618
Long-Term Investments		 - - - 36 82 54 144 145 122 661 615
Intangible Assets		 - - - - - - - - - - 0.77
Other Noncurrent Operating Assets		 3.12 2.91 2.70 2.26 2.03 1.79 0.88 0.63 0.36 1.32 1.64
Total Liabilities & Shareholders' Equity		 98 133 107 250 441 416 479 453 396 1,460 1,390
Total Liabilities		 34 28 20 21 22 34 40 49 53 50 49
Total Current Liabilities		 30 24 17 19 21 33 40 49 53 50 49
Accounts Payable		 17 8.01 7.17 9.40 8.20 15 23 29 31 31 23
Accrued Expenses		 9.35 13 6.98 6.98 10 15 16 19 22 18 25
Other Current Liabilities		 1.04 1.06 1.10 1.16 1.19 1.22 1.07 0.76 0.44 1.44 1.09
Total Noncurrent Liabilities		 4.00 3.44 3.18 1.93 1.34 0.73 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 64 106 87 230 419 383 439 404 344 1,410 1,341
Total Preferred & Common Equity		 64 106 87 230 419 383 439 404 344 1,410 1,341
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 64 106 87 230 419 383 439 404 344 1,410 1,341
Common Stock		 633 708 714 923 1,145 1,159 1,345 1,381 1,394 2,644 2,660
Retained Earnings		 -568 -602 -627 -693 -726 -778 -906 -977 -1,051 -1,233 -1,316
Accumulated Other Comprehensive Income / (Loss)		 -0.02 0.00 0.00 0.00 -0.07 1.33 0.66 0.40 0.50 -1.59 -2.67

Annual Metrics And Ratios for Praxis Precision Medicines

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 249.53% -100.00%
EBITDA Growth		 0.00% -72.80% -167.19% -28.80% 42.24% -52.67% -63.61%
EBIT Growth		 0.00% -72.76% -170.64% -27.91% 42.40% -48.30% -65.88%
NOPAT Growth		 0.00% -73.15% -170.03% -28.48% 41.22% -58.39% -62.96%
Net Income Growth		 0.00% -74.08% -170.24% -28.11% 42.40% -48.30% -65.88%
EPS Growth		 0.00% 70.45% 49.87% -28.11% 73.17% 45.37% -32.03%
Operating Cash Flow Growth		 0.00% -57.46% -136.69% -48.56% 39.94% -18.55% -89.04%
Free Cash Flow Firm Growth		 0.00% 0.00% -159.92% -49.44% 33.06% -26.14% -60.15%
Invested Capital Growth		 0.00% -94.62% -174.28% 2.85% 52.30% -107.02% -99.15%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 26.66% 432.90% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% -24.46% 7.70% 10.30% -21.56% -10.65%
EBIT Q/Q Growth		 0.00% 0.00% -24.70% 7.82% 10.39% -21.06% -11.07%
NOPAT Q/Q Growth		 0.00% 0.00% -24.52% 7.41% 9.75% -22.04% -11.29%
Net Income Q/Q Growth		 0.00% 0.00% -24.50% 7.52% 10.39% -21.06% -11.07%
EPS Q/Q Growth		 0.00% 0.00% -30.46% 7.52% -22.80% -27.63% -8.53%
Operating Cash Flow Q/Q Growth		 0.00% -24.26% -24.65% 7.98% 4.26% -32.42% -8.83%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.90% 1.03% -26.87% -8.74%
Invested Capital Q/Q Growth		 0.00% 0.00% -36.05% -31.25% 18.83% 15.54% -5.02%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -5,018.31% -2,191.87% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -5,164.41% -2,340.29% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -5,037.88% -2,137.48% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -5,037.88% -2,137.48% 0.00%
Tax Burden Percent		 99.76% 99.99% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.46% 100.00% 99.84% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -88.53% -37.74% -62.07% -130.94% -169.13% -70.98% -45.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -121.41% -64.03% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -121.41% -64.03% 0.00%
Return on Common Equity (ROCE)		 178.79% -23.79% -62.07% -130.94% -169.13% -70.98% -45.83%
Return on Equity Simple (ROE_SIMPLE)		 43.84% -21.51% -66.61% -281.22% -176.95% -41.04% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -43 -117 -150 -88 -140 -228
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -3,615.08% -1,638.20% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -23.34% -10.80% -17.44% -33.76% -38.30% -15.51% -10.74%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -126.97% -31.45% -26.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 1,718.59% 658.31% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 3,545.81% 1,781.98% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 5,264.41% 2,440.29% 0.00%
Earnings before Interest and Taxes (EBIT)		 -36 -62 -167 -214 -123 -183 -303
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -62 -165 -213 -123 -187 -307
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 7.32 3.52 1.47 2.74 3.22 8.39
Price to Tangible Book Value (P/TBV)		 0.00 7.32 3.52 1.47 2.74 3.22 8.39
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 78.03 167.70 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 44.81 112.81 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.12 -1.04 -1.06 -1.15 -1.25 -1.07 -1.05
Leverage Ratio		 1.19 1.07 1.11 1.25 1.39 1.11 1.07
Compound Leverage Factor		 1.18 1.07 1.11 1.25 1.39 1.11 1.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 301.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -201.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.25 80.12 10.26 -10.07 -7.80 20.11 71.93
Noncontrolling Interest Sharing Ratio		 301.95% 36.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 6.67 19.23 7.48 3.23 5.39 10.77 10.22
Quick Ratio		 6.57 18.87 7.18 2.93 5.16 10.45 10.03
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -39 -101 -151 -101 -128 -204
Operating Cash Flow to CapEx		 -32,446.60% 0.00% -11,862.29% -41,676.35% -222,272.00% 0.00% -444,764.29%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.02 0.03 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 3.14 20.91 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -4.70 -9.15 -25 -24 -12 -24 -48
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.14 -0.48 0.00
Increase / (Decrease) in Invested Capital		 0.00 -4.45 -16 0.72 13 -12 -24
Enterprise Value (EV)		 217 1,809 608 12 110 965 6,445
Market Capitalization		 141 2,105 884 112 191 1,434 7,371
Book Value per Share		 ($52.96) $7.51 $5.59 $1.62 $0.54 $23.90 $35.12
Tangible Book Value per Share		 ($52.96) $7.51 $5.59 $1.62 $0.54 $23.90 $35.12
Total Capital		 40 287 251 76 70 445 878
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -45 -297 -276 -100 -81 -470 -926
Capital Expenditures (CapEx)		 0.10 0.00 1.05 0.44 0.05 0.00 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.14 -10 -27 -24 -12 -26 -48
Debt-free Net Working Capital (DFNWC)		 39 287 249 76 69 367 551
Net Working Capital (NWC)		 39 287 249 76 69 367 551
Net Nonoperating Expense (NNE)		 10 18 50 64 35 43 75
Net Nonoperating Obligations (NNO)		 -45 -297 -276 -100 -81 -470 -926
Total Depreciation and Amortization (D&A)		 0.04 0.05 2.27 1.42 0.48 -4.65 -3.45
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -497.30% -301.01% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 2,825.13% 4,288.81% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 2,825.13% 4,288.81% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($117.90) ($59.10) ($69.60) ($18.69) ($10.21) ($13.48)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.57M 2.83M 3.07M 6.59M 17.91M 22.50M
Adjusted Diluted Earnings per Share		 $0.00 ($117.90) ($59.10) ($69.60) ($18.69) ($10.21) ($13.48)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.57M 2.83M 3.07M 6.59M 17.91M 22.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($117.90) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 596.68K 3.03M 3.49M 13.24M 20.16M 27.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -43 -117 -150 -88 -140 -228
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -3,615.08% -1,638.20% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -5,037.88% -2,137.48% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.34% -0.12% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Praxis Precision Medicines

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 27,850,833.00 27,878,774.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 27,850,833.00 27,878,774.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -3.32 -3.00
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -36.90% -54.29% -35.47% 1,349.13% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 34.51% -5.95% 0.30% -119.48% -124.24% -78.31% -111.34% -38.64% -49.20% -32.21% -17.08%
EBIT Growth		 34.72% -5.60% 4.77% -110.74% -118.32% -75.20% -117.67% -42.43% -51.52% -33.57% -17.71%
NOPAT Growth		 32.92% -9.96% -7.23% -122.74% -130.01% -78.41% -102.91% -37.87% -51.74% -41.66% -27.39%
Net Income Growth		 34.72% -5.60% 4.77% -110.74% -118.32% -75.20% -117.67% -42.43% -51.52% -33.57% -17.71%
EPS Growth		 69.55% 73.16% 76.42% -1.10% 19.61% -15.85% -90.23% -22.18% -20.43% 2.74% 13.29%
Operating Cash Flow Growth		 17.17% 36.50% 12.61% -18.46% -135.20% -154.16% -100.44% -136.57% -36.00% -62.52% -41.82%
Free Cash Flow Firm Growth		 -8.35% -0.72% 6.64% -15.82% -0.33% 10.69% 15.33% -47.22% -36.31% -108.63% -203.06%
Invested Capital Growth		 52.30% 36.28% 21.12% -98.95% -107.02% -141.14% -187.96% -60.17% -99.15% -15.34% 22.69%
Revenue Q/Q Growth		 10.04% -16.31% -17.17% -15.41% 2,371.19% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.15% -47.66% 13.72% -57.83% -11.52% -17.42% -2.26% -3.54% -20.01% -4.05% 9.45%
EBIT Q/Q Growth		 -9.12% -47.16% 17.38% -58.86% -13.04% -18.09% -2.64% -3.95% -20.26% -4.11% 9.55%
NOPAT Q/Q Growth		 -8.97% -50.64% 10.50% -51.61% -12.53% -16.84% -1.79% -3.01% -23.85% -9.08% 8.46%
Net Income Q/Q Growth		 -9.12% -47.16% 17.38% -58.86% -13.04% -18.09% -2.64% -3.95% -20.26% -4.11% 9.55%
EPS Q/Q Growth		 -50.00% 30.39% 38.73% -58.05% -19.27% -0.30% -0.61% -1.51% -17.56% 18.99% 10.31%
Operating Cash Flow Q/Q Growth		 -2.78% 12.59% -30.79% -0.81% -104.08% 5.55% -3.14% -18.99% -17.32% -12.88% 9.99%
Free Cash Flow Firm Q/Q Growth		 -45.71% -15.06% 18.57% 15.17% -26.23% -2.43% 22.80% -47.50% -16.87% -56.77% -12.14%
Invested Capital Q/Q Growth		 18.83% -16.98% -8.27% -93.52% 15.54% -36.26% -29.29% -7.64% -5.02% 21.08% 13.33%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -5,197.48% -9,170.53% -9,552.10% -17,822.19% -804.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -5,399.22% -9,718.33% -10,500.84% -18,819.54% -856.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -5,219.03% -9,177.03% -9,153.22% -17,188.74% -786.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -5,219.03% -9,177.03% -9,153.22% -17,188.74% -786.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -169.13% -85.25% -47.16% -64.34% -70.98% -63.56% -60.98% -75.20% -45.83% -35.32% -38.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -125.78% -115.50% -56.43% -105.50% -23.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -125.78% -115.50% -56.43% -105.50% -23.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -169.13% -85.25% -47.16% -64.34% -70.98% -63.56% -60.98% -75.20% -45.83% -35.32% -38.86%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -54.59% -29.53% -39.46% 0.00% -48.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -29 -26 -40 -45 -52 -53 -55 -68 -74 -68
NOPAT Margin		 -3,779.46% -6,802.83% -7,350.59% -13,173.68% -599.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.16% -6.22% -2.31% -4.73% -5.05% -4.75% -4.06% -4.77% -3.01% -1.92% -1.75%
Return On Investment Capital (ROIC_SIMPLE)		 -27.94% - - - -10.05% -11.91% -13.17% -15.97% -7.74% -5.26% -5.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,928.74% 3,557.54% 2,964.99% 5,051.66% 202.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 3,570.49% 6,260.79% 7,635.85% 13,867.88% 754.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 5,499.22% 9,818.33% 10,600.84% 18,919.54% 956.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93 -84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -40 -34 -54 -60 -70 -72 -75 -90 -93 -84
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.74 3.52 1.69 2.67 3.22 1.74 2.12 3.25 8.39 6.36 6.96
Price to Tangible Book Value (P/TBV)		 2.74 3.52 1.69 2.67 3.22 1.74 2.12 3.25 8.39 6.36 6.96
Price to Revenue (P/Rev)		 78.03 368.02 399.54 636.60 167.70 94.01 110.30 149.46 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 44.81 257.18 154.57 380.42 112.81 35.90 52.78 97.31 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.25 -1.12 -1.06 -1.09 -1.07 -1.07 -1.07 -1.10 -1.05 -1.04 -1.04
Leverage Ratio		 1.39 1.19 1.10 1.11 1.11 1.09 1.09 1.12 1.07 1.05 1.06
Compound Leverage Factor		 1.39 1.19 1.10 1.11 1.11 1.09 1.09 1.12 1.07 1.05 1.06
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.18 19.92 17.70 16.17 20.96 9.22 7.73 9.02 72.68 106.39 113.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.39 11.27 17.30 10.96 10.77 8.44 6.31 5.18 10.22 15.88 15.73
Quick Ratio		 5.16 11.04 17.06 10.86 10.45 8.30 6.20 5.05 10.03 15.66 15.46
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -32 -37 -30 -26 -32 -33 -26 -38 -44 -69 -77
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% -82,828.13% 0.00% 0.00% 0.00% -138,954.84% -7,617.09%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.01 0.01 0.01 0.03 0.02 0.02 0.02 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.14 3.27 3.14 3.29 20.91 22.47 24.77 33.10 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 -14 -15 -29 -24 -33 -42 -46 -48 -38 -33
Invested Capital Turnover		 -0.14 -0.13 -0.11 -0.07 -0.48 -0.35 -0.27 -0.20 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 13 7.75 3.94 -14 -12 -19 -28 -17 -24 -5.03 9.62
Enterprise Value (EV)		 110 565 274 611 965 292 410 726 6,445 7,525 7,960
Market Capitalization		 191 808 708 1,022 1,434 764 857 1,115 7,371 8,973 9,334
Book Value per Share		 $0.54 $17.35 $24.50 $21.55 $23.90 $21.78 $19.85 $16.32 $35.12 $50.63 $48.10
Tangible Book Value per Share		 $0.54 $17.35 $24.50 $21.55 $23.90 $21.78 $19.85 $16.32 $35.12 $50.63 $48.08
Total Capital		 70 230 419 383 445 439 404 344 878 1,410 1,341
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -81 -243 -434 -411 -470 -472 -447 -389 -926 -1,448 -1,374
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.06 -0.01 0.00 0.00 0.06 1.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -14 -16 -30 -26 -34 -43 -46 -48 -39 -36
Debt-free Net Working Capital (DFNWC)		 69 193 336 327 367 294 258 221 551 748 723
Net Working Capital (NWC)		 69 193 336 327 367 294 258 221 551 748 723
Net Nonoperating Expense (NNE)		 7.41 10 6.44 12 14 17 18 19 21 18 16
Net Nonoperating Obligations (NNO)		 -81 -243 -434 -411 -470 -472 -447 -389 -926 -1,448 -1,374
Total Depreciation and Amortization (D&A)		 0.11 0.03 -1.42 -1.91 -1.34 -1.18 -0.94 -0.69 -0.64 -0.62 -0.66
Debt-free, Cash-free Net Working Capital to Revenue		 -497.30% -656.31% -891.19% -1,859.50% -301.01% -417.85% -557.68% -619.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 2,825.13% 8,793.17% 18,977.75% 20,385.48% 4,288.81% 3,620.45% 3,322.23% 2,960.75% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 2,825.13% 8,793.17% 18,977.75% 20,385.48% 4,288.81% 3,620.45% 3,322.23% 2,960.75% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20) ($2.87)
Adjusted Weighted Average Basic Shares Outstanding		 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M 29.13M
Adjusted Diluted Earnings per Share		 ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20) ($2.87)
Adjusted Weighted Average Diluted Shares Outstanding		 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M 29.13M
Adjusted Basic & Diluted Earnings per Share		 ($4.08) $0.00 $0.00 $0.00 ($3.28) $0.00 $0.00 $0.00 ($3.95) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.24M 17.11M 17.76M 18.64M 20.16M 20.37M 21.05M 25.01M 27.85M 27.88M 27.92M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -29 -26 -40 -45 -52 -53 -55 -68 -74 -68
Normalized NOPAT Margin		 -3,779.46% -6,802.83% -7,350.59% -13,173.68% -599.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -5,219.03% -9,177.03% -9,153.22% -17,188.74% -786.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Praxis Precision Medicines (NASDAQ:PRAX) remains a development-stage biotechnology company with no meaningful operating revenue. Revenue declined from small amounts in 2023 and 2024 to zero in each reported quarter from Q2 2025 through Q2 2026. As a result, the company continues to depend on cash, investment income and equity financing to fund research and development.

Operating expenses have increased substantially over the period. Quarterly research and development expense rose from $18.4 million in Q4 2022 to $69.4 million in Q2 2026, while total operating expenses reached $96.9 million. Quarterly net losses widened from $41.2 million in Q4 2022 to $83.7 million in Q2 2026, although the latest loss was narrower than the $92.6 million loss in Q1 2026.

The balance sheet is substantially stronger than it was in 2022 and 2023, primarily because of large equity raises. As of June 30, 2026, Praxis reported $474.8 million in cash, $283.8 million in short-term investments and $615.3 million in long-term investments. Total liabilities were only $49.1 million, with no noncurrent liabilities reported. However, the company’s accumulated retained-earnings deficit reached $1.32 billion, reflecting years of operating losses.

Cash burn remains the key financial risk. Operating cash outflow was $53.0 million in Q1 2025, $76.3 million in Q4 2025, $86.2 million in Q1 2026 and $77.5 million in Q2 2026. At the Q2 2026 operating cash-burn rate, the company’s cash and investment portfolio provides significant financial flexibility, but the duration of that runway will depend on clinical spending, potential commercialization costs and future financing needs.

  • Large liquidity position: Cash, short-term investments and long-term investments totaled approximately $1.37 billion at the end of Q2 2026, providing a substantial funding base for ongoing clinical development.
  • Minimal leverage: Total liabilities were $49.1 million and Praxis reported no noncurrent liabilities, limiting interest-rate and debt-refinancing risk.
  • Improved balance-sheet scale: Total assets increased from $136.9 million in Q3 2022 to $1.39 billion in Q2 2026, largely following equity financings that strengthened the company’s capital base.
  • Research spending supports pipeline development: R&D expense remained high at $69.4 million in Q2 2026, indicating continued investment in the company’s drug-development programs.
  • Investment income partially offsets operating losses: Net other income was $13.2 million in Q2 2026, helping reduce the quarterly pretax loss from the $96.9 million operating loss to $83.7 million.
  • Operating cash burn fluctuates but remains elevated: Operating cash outflow improved modestly from $86.2 million in Q1 2026 to $77.5 million in Q2 2026, but remains considerably higher than the $23.9 million outflow in Q4 2023.
  • Investment activity mainly reflects treasury management: Large purchases, sales and maturities of investments have caused significant quarter-to-quarter swings in investing cash flow, making total cash changes less indicative of underlying operating performance.
  • No current revenue base: Praxis reported zero revenue in Q2 2025, Q3 2025, Q4 2025, Q1 2026 and Q2 2026, leaving the company without recurring operating income to fund expenses.
  • Persistent and growing losses: Quarterly net losses were $71.1 million in Q2 2025, $88.9 million in Q4 2025, $92.6 million in Q1 2026 and $83.7 million in Q2 2026. The company is not close to profitability based on the latest statements.
  • Heavy reliance on equity financing creates dilution risk: Praxis raised approximately $613.3 million in Q4 2025 and $621.2 million in Q1 2026 through common equity issuance. Weighted-average basic shares increased from 17.9 million in Q4 2024 to 29.1 million in Q2 2026, potentially reducing each existing shareholder’s ownership percentage.

Overall, Praxis has a well-capitalized, low-debt balance sheet, but its financial profile remains dependent on successful clinical development and eventual product commercialization. The improving liquidity position is a meaningful positive, while the absence of revenue, continued operating cash burn and repeated equity issuance remain the most important issues for investors to monitor.

09/18/26 09:50 PM ETAI Generated. May Contain Errors.

Praxis Precision Medicines Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Praxis Precision Medicines' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Praxis Precision Medicines' net income appears to be on an upward trend, with a most recent value of -$303.27 million in 2025, rising from -$35.51 million in 2019. The previous period was -$182.82 million in 2024. Check out Praxis Precision Medicines' forecast to explore projected trends and price targets.

Praxis Precision Medicines' total operating income in 2025 was -$326.20 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $326.20 million

Over the last 6 years, Praxis Precision Medicines' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Praxis Precision Medicines' total liabilities were at $59.77 million at the end of 2025, a 58.7% increase from 2024, and a 688.4% increase since 2019.

In the past 6 years, Praxis Precision Medicines' cash and equivalents has ranged from $44.82 million in 2019 to $357.33 million in 2025, and is currently $357.33 million as of their latest financial filing in 2025.

Over the last 6 years, Praxis Precision Medicines' book value per share changed from -52.96 in 2019 to 35.12 in 2025, a change of -166.3%.


Related Companies

Financial statements for NASDAQ:PRAX last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Iran War WARNING: Something Just Changed
A powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...
Banyan Hill Publishing | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel